With only one medication historically used to treat diabetic kidney disease, study of combination therapies with newer ...

Discover six kidney disease companies actively working on innovative treatments that could make a difference to patients' lives.

EXCLUSIVE: The dialysis company believes the impact of the treatments on its own performance will be ‘neutral to positive’ ...

While the renal benefits of oral semaglutide vs placebo in the SOUL trial didn't match the effects seen with the injectable ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

A spirited pro/con debate at ERA 2025 explores whether population-level albuminuria screening could improve early CKD ...

An international clinical trial, led in the UK by Swansea’s Joint Clinical Research Facility (JCRF), has found that ...

Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline ...

The diabetic nephropathy market is driven by the growing burden of diabetes and the increasing demand for effective treatments for kidney disease. Advances in therapeutics, including new drug classes ...

The pathophysiology of vascular disease is linked to accelerated biological aging and a combination of genetic, lifestyle, biological, and environmental risk factors. Within the scenario of ...